查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球功效测试市场：按服务类型（抗菌和防腐效果测试、杀菌效果测试）、按应用（製药、化妆品和个人护理产品、医疗器械、消费品）、按地区 - 到 2027 年预测
市场调查报告书
商品编码
1105262

全球功效测试市场：按服务类型（抗菌和防腐效果测试、杀菌效果测试）、按应用（製药、化妆品和个人护理产品、医疗器械、消费品）、按地区 - 到 2027 年预测

Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 176 Pages | 订单完成后即时交付

价格
简介目录

全球疗效试验市场规模将从 2022 年的 3.15 亿美元到 2027 年达到 4.23 亿美元，在预测期内以 6.1% 的复合年增长率增长。

这一市场增长的主要驱动力是表面消毒剂和防腐剂在污染控制和产品稳定性方面的使用越来越多，以及药效测试外包（主要在製药、生物製药和化妆品行业），以及越来越多的采用的 QbD 方法。新兴市场的高增长潜力预计将为在功效试验市场上运营的公司提供增长机会。

“按服务类型来看，常规检测在抗菌防腐效果检测市场中占比最大”

传统测试通常需要在很长一段时间内在多个测试点进行微生物检测。试用期通常从最少 28 天到 12 週或更长时间不等。执行检测不需要特殊设备或培训，因为它涉及标准微生物技术，类似于长期一般挑战方案中使用的技术。事实上，这种加速双重挑战 (ADC) 测定目前在许多实验室中以其基本形式或用于各种应用的变体形式使用。

“按应用来看，医药製造板块在预测期内将呈现最高增长率”

按应用，功效测试市场细分为药品製造应用、化妆品和个人护理产品应用、消费品应用和医疗设备应用。 2021 年，製药应用□□是市场上最大的产品部分。这一市场增长可归因于主要製药公司增加研发製造、政府支持、製药行业的增长以及对患者安全的关注。

“预计亚太市场将在预测期内（2020-2027 年）呈现最高增长率”

预计亚太市场在预测期内将以最高的复合年增长率增长。这主要是由于政府医疗保健支出增加、老年人口不断增长、消费者健康意识提高以及慢性病发病率上升，所有这些都是该地区药品增长的原因。在中国建立生产设施的製药公司数量

“北美：功效测试市场份额最大”

北美在功效测试市场中占有最大份额。该地区拥有成熟的製药行业，诸如高研发成本、大型服务提供商的存在以及该地区製药和化妆品公司增加分析测试（包括功效测试）外包等因素是市场增长的主要驱动力。

内容

第1章介绍

第2章研究方法

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 简介
  • 市场动态
    • 驱动程序
    • 约束因素
    • 机会
    • 任务
  • 监管分析
  • COVID-19 对功效测试服务的影响
  • 价格分析
  • 专利分析
  • 贸易分析
  • 价值链分析
  • 生态系统分析
  • 波特五力分析
  • 技术分析

第 6 章功效测试市场：按服务类型划分

  • 简介
  • 杀菌效果测试
    • 表面测试
    • 暂停测试
  • 抗菌防腐效果测试
    • 常规
    • 快速型

第 7 章。功效测试市场：按应用分类

  • 简介
  • 製药业
  • 化妆品和个人护理产品
  • 消费品
  • 医疗设备

第 8 章。功效研究市场：按地区划分

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 意大利
    • 西班牙
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他
  • 其他地区
    • 拉丁美洲
    • 中东和非洲

第 9 章竞争格局

  • 概览
  • 主要企业战略/领先企业
  • 市场份额分析
  • 主要市场参与者的收入份额分析
  • 企业评估象限
  • 企业评估象限：初创企业/中小企业
  • 企业足迹分析
  • 竞争场景

第 10 章公司简介

  • 功效检测服务商
    • EUROFINS SCIENTIFIC
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • WUXI APPTEC
    • SGS SA
    • INTERTEK GROUP PLC
    • MICROCHEM LABORATORY
    • ACCUGEN LABORATORIES, INC.
    • PACIFIC BIOLABS
    • NORTH AMERICAN SCIENCE ASSOCIATES
    • TOXIKON
    • BIOSCIENCE LABORATORIES, INC.
    • CONSUMER PRODUCT TESTING COMPANY (CPTC)
    • ALMAC GROUP
    • MSL SOLUTION PROVIDERS
    • NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY)
    • ALS LIMITED
    • ABBOTT ANALYTICAL
    • BLUTEST LABORATORIES LIMITED
    • LUCIDEON
    • HELVIC LABORATORIES (A TENTAMUS COMPANY)
  • 杀菌剂製造商
    • PROCTER & GAMBLE
    • THE CLOROX COMPANY
    • 3M
    • RECKITT BENCKISER GROUP PLC
    • ECOLAB
    • STERIS
    • CANTEL MEDICAL
    • DIVERSEY HOLDINGS LTD.
    • CARROLLCLEAN
    • PAUL HARTMANN AG

第11章 附录

简介目录
Product Code: BT 5932

The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

"By method type, the traditional test method accounted for the largest share of the antimicrobial/preservative testing market"

Traditional testing methods generally require microbial assays at multiple test points over extended periods of time. Test durations typically range from a minimum of 28 days to 12 or more weeks. Because standard microbiological techniques similar to those employed in longer-term generic challenge protocols are involved, no special equipment or training is necessary to perform the assay. In fact, this accelerated double challenge (ADC) assay is currently being used in its basic form or in variations at numerous laboratories for a variety of applications.

"The pharmaceutical manufacturing application segment will grow at the highest rate during the forecast period."

On the basis of application, the efficacy testing market is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications. In 2021, pharmaceutical manufacturing applications were the largest product segment in the market. Growth in this market can be attributed to the increasing R&D manufactures by leading pharmaceutical companies, government support, growth of the pharmaceutical industry, and a growing focus on patient safety.

"The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2027)."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, increasing incidence of chronic diseases thereby being responsible for the growth of pharmaceutical products in this region, and the increasing number of pharmaceutical companies that are establishing manufacturing facilities in APAC countries.

"North America: the largest share of the efficacy testing market"

North America accounted for the largest share of the efficacy testing market. Factors such as the presence of a well established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of analytical testing (including efficacy testing) by pharmaceutical and cosmetic companies in the region are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Respondent- Supply Side- 80%, Demand Side-20%
  • By Designation- Executives- 25%, CXOs- 20%, Managers - 55%
  • By Region- North America - 50%, Europe - 20%, APAC - 20%, RoW- 10%

The key players operating in the efficacy testing market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK), BioScience Laboratories, Inc. (US), ALS Limited (Australia), Microchem Laboratory (US), Oxford Biosciences Ltd. (UK), Abbott Analytical (Australia), Helvic Laboratories (a Tentamus Company, UK), Honeyman Group Limited (UK), Danish Technological Institute (DTI, Denmark), and BluTest Laboratories Limited (UK).

Research Coverage:

The report segments the efficacy testing market based on region (Asia Pacific, Europe, North America, and RoW), service type (disinfectant efficacy testing and antimicrobial/preservative efficacy testing), application (pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the efficacy testing market

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the efficacy testing market and provides them information on key market drivers, challenges, and opportunities.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the efficacy testing market. The report analyzes the market based on the service type, application, and region.
  • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service/product launches in the efficacy testing market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of efficacy testing solutions across regions.
  • Market Diversification: Exhaustive information about products/ services, untapped regions, recent developments, and investments in the efficacy testing market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the efficacy testing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primary sources
    • FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS
    • FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 EFFICACY TESTING MARKET OVERVIEW
    • FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)
    • FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET
    • FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027
  • 4.4 EFFICACY TESTING MARKET, BY REGION
    • FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027
  • 4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability
        • 5.2.1.1.1 Growing focus on contamination control
        • 5.2.1.1.2 Increasing concerns over product stability
      • 5.2.1.2 Growing preference for outsourcing efficacy testing
      • 5.2.1.3 Rising adoption of quality by design approach
      • 5.2.1.4 Stringent regulations for use of surface disinfectants
      • 5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse effects of chemical disinfectants
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging countries in Asia Pacific
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Time-consuming process
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 DISINFECTANT EFFICACY TESTING
    • 5.3.2 ANTIMICROBIAL EFFICACY TESTING
  • 5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES
  • 5.5 PRICING ANALYSIS
    • TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022)
  • 5.6 PATENT ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR DISINFECTANTS
    • TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.8 VALUE CHAIN ANALYSIS
    • FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET
  • 5.9 ECOSYSTEM ANALYSIS
    • FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS
    • TABLE 4 ROLE IN ECOSYSTEM
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 EFFICACY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 BARGAINING POWER OF SUPPLIERS
    • 5.10.5 DEGREE OF COMPETITION
  • 5.11 TECHNOLOGY ANALYSIS

6 EFFICACY TESTING MARKET, BY SERVICE TYPE

  • 6.1 INTRODUCTION
    • TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
  • 6.2 DISINFECTANT EFFICACY TESTING
    • TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.2.1 SURFACE TEST METHOD
      • 6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market
    • TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.2 SUSPENSION TEST METHOD
      • 6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants
    • TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING
    • TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL
    • TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.3.1 TRADITIONAL TEST METHOD
      • 6.3.1.1 Traditional test method segment to dominate AET/PET market
    • TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 RAPID TEST METHOD
      • 6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods
    • TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)

7 EFFICACY TESTING MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS
    • 7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS
    • 7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS
    • TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 CONSUMER PRODUCT APPLICATIONS
    • 7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH
    • TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 MEDICAL DEVICE APPLICATIONS
    • 7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH
    • TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

8 EFFICACY TESTING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 US to dominate North American efficacy testing market during forecast period
    • TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Government initiatives to drive market growth in Canada
    • TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany to account for largest share in European market
    • TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.2 FRANCE
      • 8.3.2.1 High demand for cosmetics in France to drive market growth
    • TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.3 UK
      • 8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards
    • TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth
    • TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Rising R&D expenditure to boost market growth in Spain
    • TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 China to dominate Asia Pacific market
    • TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.2 JAPAN
      • 8.4.2.1 Rising R&D investments to drive market growth in Japan
    • TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Growing pharmaceutical industry in India to drive market growth
    • TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC
    • TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 8.5.1 LATIN AMERICA
      • 8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America
    • TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.5.2 MIDDLE EAST AND AFRICA
      • 8.5.2.1 UAE has emerged as key market in MEA region
    • TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019-2022
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION
  • 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
  • 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 STARTING BLOCKS
    • 9.6.3 RESPONSIVE COMPANIES
    • 9.6.4 DYNAMIC COMPANIES
  • 9.7 FOOTPRINT ANALYSIS OF COMPANIES
    • 9.7.1 SERVICE FOOTPRINT OF COMPANIES
    • TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
    • 9.7.2 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
  • 9.8 COMPETITIVE SCENARIO
    • TABLE 111 PRODUCT LAUNCHES
    • TABLE 112 DEALS
    • TABLE 113 OTHER DEVELOPMENTS

10 COMPANY PROFILES

  • 10.1 EFFICACY TESTING SERVICE PROVIDERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 EUROFINS SCIENTIFIC
    • TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
    • 10.1.3 WUXI APPTEC
    • TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021)
    • 10.1.4 SGS SA
    • TABLE 117 SGS SA: BUSINESS OVERVIEW
    • 10.1.5 INTERTEK GROUP PLC
    • TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.1.6 MICROCHEM LABORATORY
    • TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW
    • 10.1.7 ACCUGEN LABORATORIES, INC.
    • TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.8 PACIFIC BIOLABS
    • TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW
    • 10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES
    • TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW
    • 10.1.10 TOXIKON
    • TABLE 123 TOXIKON: BUSINESS OVERVIEW
    • 10.1.11 BIOSCIENCE LABORATORIES, INC.
    • TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC)
    • TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW
    • 10.1.13 ALMAC GROUP
    • TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW
    • 10.1.14 MSL SOLUTION PROVIDERS
    • TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW
    • 10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY)
    • TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW
    • 10.1.16 ALS LIMITED
    • TABLE 129 ALS LIMITED: BUSINESS OVERVIEW
    • 10.1.17 ABBOTT ANALYTICAL
    • TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW
    • 10.1.18 BLUTEST LABORATORIES LIMITED
    • TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW
    • 10.1.19 LUCIDEON
    • TABLE 132 LUCIDEON: BUSINESS OVERVIEW
    • 10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY)
    • TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW
  • 10.2 MANUFACTURERS OF DISINFECTANTS
    • 10.2.1 PROCTER & GAMBLE
    • TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW
    • FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021)
    • 10.2.2 THE CLOROX COMPANY
    • TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW
    • FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021)
    • 10.2.3 3M
    • TABLE 136 3M: BUSINESS OVERVIEW
    • FIGURE 31 3M: COMPANY SNAPSHOT (2021)
    • 10.2.4 RECKITT BENCKISER GROUP PLC
    • TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.2.5 ECOLAB
    • TABLE 138 ECOLAB: BUSINESS OVERVIEW
    • FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021)
    • 10.2.6 STERIS
    • TABLE 139 STERIS: BUSINESS OVERVIEW
    • FIGURE 34 STERIS: COMPANY SNAPSHOT (2021)
    • 10.2.7 CANTEL MEDICAL
    • TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW
    • FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021)
    • 10.2.8 DIVERSEY HOLDINGS LTD.
    • TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW
    • FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021)
    • 10.2.9 CARROLLCLEAN
    • TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW
    • 10.2.10 PAUL HARTMANN AG
    • TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS